Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193257 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,099
- Enrollment target
NCT01193257 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 1,099 participants.
The verdict
NCT01193257, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,099 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy
Interventions
- DRUG Prednisone
- DRUG Orteronel
- DRUG Orteronel Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,099 participants |
| Start Date | 2010-11-15 |
| Est. Completion | 2016-02-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01193257
The ClinicalTrials.gov registry entry for NCT01193257 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,099 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT01193257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01193257 about?
NCT01193257 is a clinical study titled "Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.". This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy
What is the current status of trial NCT01193257?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,099 participants. The study started on 2010-11-15. Estimated completion is 2016-02-29.
What interventions are being tested in trial NCT01193257?
The interventions under investigation include: Prednisone (DRUG), Orteronel (DRUG), Orteronel Placebo (DRUG).
Who is sponsoring clinical trial NCT01193257?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.